A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Clinical trial NCT05785624 · TERMINATED

Trial details

NCT number: NCT05785624
Sponsor: Genentech, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis Systemic Sclerosis With Lung Involvement

Start date: 2023-05-26
Primary completion: 2026-01-12
Enrollment: 286

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.